Importantly, recent study showed that BRAF/TERT promoter double-mutated brain tumor cells were sensitive to YK-4-279 treatment, providing a therapeutic opportunity to manage brain tumor patients harboring both BRAF and TERT mutations (26). Here, BRAF is linked to brain neoplasm.